TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ZNTL stock, giving a Buy rating on October 27.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tyler Van Buren’s rating is based on Zentalis Pharmaceuticals’ promising clinical progress and strategic focus. The ongoing enrollment in the DENALI Part 2 study for CCNE1+ PROC, which is expected to yield significant topline data by the end of 2026, positions the company well for potential accelerated approval. This strategic focus on PROC, rather than further investment in USC, is seen as a prudent allocation of resources.
Furthermore, the clinical data from previous trials, including Phase Ia, MAMMOTH, and DENALI, have demonstrated a notable improvement over standard chemotherapy treatments. With an objective response rate of 31-35% and a median duration of response between 4.2-6.3 months, Zentalis’ azeno treatment shows a clear advantage, reinforcing the potential for successful outcomes in the ongoing trials. These factors collectively underpin the Buy rating given by Tyler Van Buren.
In another report released on October 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.